The addition of glexatinib or crizotinib to erlotinib synergistically reduced tumor growth in a patient-derived xenograft (PDX) model with consistent reduction in p-ERK1/2 and p-RPS6 in PDX tumor samples [400]. Here, MAPK3 is linked to neoplasm.